• Very promising preclinical results of the apoA-I biovector in an acute inflammation model
• Development of safe corticoids to limit traditional corticoid-related side effects when used in AMD or DME
• Project to separate the ophthalmology activities and change the name of IRIS Pharma Holding to APOGEYE Pharma

Cyrille TUPIN, Chief Executive Officer of ABIONYX Pharma Unveils Ophthalmology Strategy and Positive Preclinical Results for Innovative Technologies., said: "The acquisition of IRIS Pharma, one of the world leaders in Contract Research in ophthalmology, a little over a year ago, has borne fruit and has enabled us to structure a value-creating strategy based on our flagship asset, the only natural recombinant apoA-I lipoprotein in the world and one of the most advanced biomedicines. Indeed, studies with IRIS Pharma have determined the deployment of a strategy based on two technological platforms: apotherapy that means an innovative therapy based on our natural recombinant apoA-I alone, and biovectorization meaning incorporation of various active ingredients into our proprietary apoA-I complex used as a vector. The preclinical results of our biovector in ophthalmology are very promising, especially for corticoids, in order to optimise their efficacy while limiting their side effects, which are one of the major concerns in ophthalmology today worldwide."